CliffBio
small molecule

SUSTOL

GRANISETRON

Loss of exclusivity—loss of exclusivity
CompanyHeron Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUSTOL
Active ingredientGRANISETRON
Strength10MG/0.4ML (10MG/0.4ML)
Dosage formINJECTABLE
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalAugust 2016
Marketing statusRX

More from Heron Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SUSTOL patent cliff — loss of exclusivity — | CliffBio